10X GENOMICS INC-CLASS A (TXG) Fundamental Analysis & Valuation

NASDAQ:TXG • US88025U1097

Current stock price

23 USD
-0.02 (-0.09%)
At close:
23.3 USD
+0.3 (+1.3%)
After Hours:

This TXG fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. TXG Profitability Analysis

1.1 Basic Checks

  • In the past year TXG has reported negative net income.
  • In the past year TXG had a positive cash flow from operations.
  • In the past 5 years TXG always reported negative net income.
  • In multiple years TXG reported negative operating cash flow during the last 5 years.
TXG Yearly Net Income VS EBIT VS OCF VS FCFTXG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200M -400M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -4.18%, TXG is in line with its industry, outperforming 56.14% of the companies in the same industry.
  • The Return On Equity of TXG (-5.47%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -4.18%
ROE -5.47%
ROIC N/A
ROA(3y)-16.83%
ROA(5y)-14.47%
ROE(3y)-21.87%
ROE(5y)-18.67%
ROIC(3y)N/A
ROIC(5y)N/A
TXG Yearly ROA, ROE, ROICTXG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300 -400

1.3 Margins

  • The Gross Margin of TXG (69.13%) is better than 91.23% of its industry peers.
  • In the last couple of years the Gross Margin of TXG has declined.
  • The Profit Margin and Operating Margin are not available for TXG so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 69.13%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.4%
GM growth 5Y-2.99%
TXG Yearly Profit, Operating, Gross MarginsTXG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. TXG Health Analysis

2.1 Basic Checks

  • TXG does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for TXG has been increased compared to 1 year ago.
  • TXG has more shares outstanding than it did 5 years ago.
  • TXG has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TXG Yearly Shares OutstandingTXG Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
TXG Yearly Total Debt VS Total AssetsTXG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • An Altman-Z score of 6.08 indicates that TXG is not in any danger for bankruptcy at the moment.
  • TXG's Altman-Z score of 6.08 is amongst the best of the industry. TXG outperforms 87.72% of its industry peers.
  • There is no outstanding debt for TXG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 6.08
ROIC/WACCN/A
WACC10.9%
TXG Yearly LT Debt VS Equity VS FCFTXG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M 600M 800M

2.3 Liquidity

  • A Current Ratio of 4.46 indicates that TXG has no problem at all paying its short term obligations.
  • The Current ratio of TXG (4.46) is better than 71.93% of its industry peers.
  • A Quick Ratio of 4.09 indicates that TXG has no problem at all paying its short term obligations.
  • TXG has a better Quick ratio (4.09) than 75.44% of its industry peers.
Industry RankSector Rank
Current Ratio 4.46
Quick Ratio 4.09
TXG Yearly Current Assets VS Current LiabilitesTXG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. TXG Growth Analysis

3.1 Past

  • TXG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 71.71%, which is quite impressive.
  • The Revenue has been growing slightly by 5.25% in the past year.
  • Measured over the past years, TXG shows a quite strong growth in Revenue. The Revenue has been growing by 16.56% on average per year.
EPS 1Y (TTM)71.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.5%
Revenue 1Y (TTM)5.25%
Revenue growth 3Y7.57%
Revenue growth 5Y16.56%
Sales Q2Q%0.61%

3.2 Future

  • The Earnings Per Share is expected to grow by 26.18% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, TXG will show a small growth in Revenue. The Revenue will grow by 5.75% on average per year.
EPS Next Y-126.62%
EPS Next 2Y-33.01%
EPS Next 3Y-5.65%
EPS Next 5Y26.18%
Revenue Next Year-3.5%
Revenue Next 2Y1.77%
Revenue Next 3Y3.9%
Revenue Next 5Y5.75%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
TXG Yearly Revenue VS EstimatesTXG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
TXG Yearly EPS VS EstimatesTXG Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -1 -2 -3 -4 -5

More info and screens

Find the best growth stocksShow best growing peers

1

4. TXG Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for TXG. In the last year negative earnings were reported.
  • Also next year TXG is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TXG Price Earnings VS Forward Price EarningsTXG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40

4.2 Price Multiples

  • 75.44% of the companies in the same industry are more expensive than TXG, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 22.58
EV/EBITDA N/A
TXG Per share dataTXG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

  • TXG's earnings are expected to decrease with -5.65% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-33.01%
EPS Next 3Y-5.65%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TXG Dividend Analysis

5.1 Amount

  • No dividends for TXG!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TXG Fundamentals: All Metrics, Ratios and Statistics

10X GENOMICS INC-CLASS A

NASDAQ:TXG (4/9/2026, 8:03:07 PM)

After market: 23.3 +0.3 (+1.3%)

23

-0.02 (-0.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-12
Earnings (Next)05-06
Inst Owners107%
Inst Owner Change0%
Ins Owners1.61%
Ins Owner Change9.29%
Market Cap2.94B
Revenue(TTM)642.82M
Net Income(TTM)-43.54M
Analysts72.73
Price Target20.69 (-10.04%)
Short Float %13.72%
Short Ratio6.21
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)31.91%
Min EPS beat(2)24.4%
Max EPS beat(2)39.41%
EPS beat(4)4
Avg EPS beat(4)65.69%
Min EPS beat(4)24.36%
Max EPS beat(4)174.61%
EPS beat(8)7
Avg EPS beat(8)34.54%
EPS beat(12)7
Avg EPS beat(12)12.19%
EPS beat(16)9
Avg EPS beat(16)9.62%
Revenue beat(2)2
Avg Revenue beat(2)3.37%
Min Revenue beat(2)3.21%
Max Revenue beat(2)3.54%
Revenue beat(4)4
Avg Revenue beat(4)11.32%
Min Revenue beat(4)3.21%
Max Revenue beat(4)22.78%
Revenue beat(8)6
Avg Revenue beat(8)5.2%
Revenue beat(12)9
Avg Revenue beat(12)4.07%
Revenue beat(16)12
Avg Revenue beat(16)3.14%
PT rev (1m)1.79%
PT rev (3m)17.94%
EPS NQ rev (1m)-0.54%
EPS NQ rev (3m)-3.72%
EPS NY rev (1m)0%
EPS NY rev (3m)-1%
Revenue NQ rev (1m)0.2%
Revenue NQ rev (3m)2.81%
Revenue NY rev (1m)0.06%
Revenue NY rev (3m)0.63%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.57
P/FCF 22.58
P/OCF 21.6
P/B 3.69
P/tB 4.03
EV/EBITDA N/A
EPS(TTM)-0.43
EYN/A
EPS(NY)-0.97
Fwd EYN/A
FCF(TTM)1.02
FCFY4.43%
OCF(TTM)1.06
OCFY4.63%
SpS5.03
BVpS6.23
TBVpS5.71
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -4.18%
ROE -5.47%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 69.13%
FCFM 20.24%
ROA(3y)-16.83%
ROA(5y)-14.47%
ROE(3y)-21.87%
ROE(5y)-18.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.4%
GM growth 5Y-2.99%
F-Score5
Asset Turnover0.62
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 16.4%
Cap/Sales 0.92%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.46
Quick Ratio 4.09
Altman-Z 6.08
F-Score5
WACC10.9%
ROIC/WACCN/A
Cap/Depr(3y)64.39%
Cap/Depr(5y)238.34%
Cap/Sales(3y)3.71%
Cap/Sales(5y)11.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)71.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.5%
EPS Next Y-126.62%
EPS Next 2Y-33.01%
EPS Next 3Y-5.65%
EPS Next 5Y26.18%
Revenue 1Y (TTM)5.25%
Revenue growth 3Y7.57%
Revenue growth 5Y16.56%
Sales Q2Q%0.61%
Revenue Next Year-3.5%
Revenue Next 2Y1.77%
Revenue Next 3Y3.9%
Revenue Next 5Y5.75%
EBIT growth 1Y48.26%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-237.31%
EBIT Next 3Y-11.54%
EBIT Next 5Y6.3%
FCF growth 1Y2033.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1941.57%
OCF growth 3YN/A
OCF growth 5YN/A

10X GENOMICS INC-CLASS A / TXG Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for 10X GENOMICS INC-CLASS A?

ChartMill assigns a fundamental rating of 4 / 10 to TXG.


What is the valuation status of 10X GENOMICS INC-CLASS A (TXG) stock?

ChartMill assigns a valuation rating of 1 / 10 to 10X GENOMICS INC-CLASS A (TXG). This can be considered as Overvalued.


What is the profitability of TXG stock?

10X GENOMICS INC-CLASS A (TXG) has a profitability rating of 2 / 10.


What is the earnings growth outlook for 10X GENOMICS INC-CLASS A?

The Earnings per Share (EPS) of 10X GENOMICS INC-CLASS A (TXG) is expected to decline by -126.62% in the next year.